Q&A

Q&A
Will Herrington, MA, MBBS, MD
Q&A
Effects of Empagliflozin in Patients With Chronic Kidney Disease
03/24/2023
In this Q&A, Chief Investigator of the EMPA-KIDNEY trial, William Herrington, MA, MBBS, MD, answers questions about the results of the trial, including the effects of the SGLT2 inhibitor, empagliflozin,...
03/24/2023
Expert Q&A
Dr Castillo-Angeles
Expert Q&A
Frailty and Mortality Following Surgery
03/23/2023
In this Q&A, Manuel Castillo-Angeles, MD, MPH, postdoctoral research fellow at the Center for Surgery and Public Health, Brigham and Women’s Hospital discusses the results of a recent study on the effects...
03/23/2023
Expert Q&A
blood cells
Expert Q&A
The Use of Blood Cell Count for Asthma Phenotype Identification
03/19/2023
03/19/2023
Expert Q&A
Dr Tang
Expert Q&A
Will New ADA Guidelines Impact GLP-1 RA, SGLT-2 Inhibitor Usage?
03/14/2023
03/14/2023
Expert Q&A
Jordana Cohen
Expert Q&A
AHA Statement Addresses Anticancer Therapy-Induced Hypertension
03/13/2023
03/13/2023
Expert Q&A
steven e nissen, md
Expert Q&A
Bempedoic Acid: The Answer to a “Vexing Clinical Problem”
03/08/2023
03/08/2023
Expert Q&A
jacob
Expert Q&A
Increased Risk of Post-Discharge CVD Events Among Survivors of Sepsis
03/02/2023
03/02/2023
Expert Q&A
Grant Waterer
Expert Q&A
ATS Guidelines on the Diagnosis and Treatment of Adults With CAP
03/01/2023
In this Q and A, Grant Waterer, MBBS, PhD, MBA, answers questions on the recommendations regarding the diagnosis of adults with community-acquired pneumonia, including consideration for inpatient vs...
03/01/2023
Depression Care360
Dr Thomas van Sloten, MD
Depression Care360
New Study Ties Cardiovascular Health to Depressive Symptoms
02/28/2023
02/28/2023
Expert Q&A
Expert Q&A
Rapid Hepatitis C Virus Treatment Initiation
02/27/2023
As the number of new hepatitis C virus infections continues to rise in the United States, rapid diagnosis and treatment of high-risk patients is more important than ever. In this Q&A, Benjamin Eckhardt, MD,...
02/27/2023